Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar

Eli Lilly reported robust third-quarter results, significantly exceeding analyst estimates for both earnings and revenue, propelled by exceptional demand for its GLP-1 drugs, Mounjaro and Zepbound, which generated $6.52 billion (+109%) and $3.57 billion (+184%) in revenue, respectively. This strong performance led the company to raise its full-year 2025 revenue guidance to $63-$63.5 billion and its adjusted EPS outlook, reinforcing its dominant position in the rapidly expanding GLP-1 market amidst fierce competition from rivals like Novo Nordisk. The positive news resulted in a 5% premarket share increase and underscores Lilly's strategic focus on maintaining market leadership through initiatives such as the Walmart partnership for Zepbound and the development of its experimental obesity pill, orforglipron.

Analysis

Eli Lilly (LLY) significantly surpassed Q3 analyst expectations, reporting adjusted EPS of $7.02 against $5.69 expected and revenue of $17.60 billion versus $16.01 billion. This robust performance, representing a 54% year-over-year revenue increase, prompted a 5% premarket share surge. The company subsequently raised its full-year 2025 revenue guidance to $63-$63.5 billion and adjusted EPS to $23-$23.70, signaling continued strong operational momentum.

The exceptional results were primarily driven by blockbuster GLP-1 drugs, Mounjaro and Zepbound, which generated $6.52 billion (up 109% YoY) and $3.57 billion (up 184% YoY) in revenue, respectively, both exceeding StreetAccount estimates. A 60% increase in prescription volume for these key products underscores Eli Lilly's expanding market share in the booming obesity and diabetes treatment space. Despite some offset from lower realized prices, demand remains exceptionally strong.

Eli Lilly is actively solidifying its market leadership against chief rival Novo Nordisk (NVO), evidenced by its recent partnership with Walmart to enhance Zepbound access and the development of its experimental obesity pill, orforglipron. The competitive intensity is highlighted by Novo Nordisk's rival bid for Metsera, aiming to catch up in the GLP-1 market. Future tariff policies, specifically threatened levies on imported pharmaceuticals, remain a potential, unquantified risk to future guidance.

Key Decisions for Investors

• Investors should consider Eli Lilly's sustained outperformance and raised guidance, driven by robust demand for its GLP-1 portfolio, as a strong indicator of continued market leadership and earnings growth potential.
• Monitor competitive developments, particularly from Novo Nordisk's strategic M&A activities and the progress of Eli Lilly's pipeline assets like orforglipron, which are crucial for long-term dominance in the rapidly evolving GLP-1 market.
• Evaluate the potential impact of future trade policies, specifically any new tariffs on pharmaceutical imports, as current guidance does not account for these threatened levies, which could introduce unforeseen cost pressures.